Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS).

MedStar author(s):
Citation: Lupus. 25(9):1050-3, 2016 AugPMID: 26911153Institution: MedStar Washington Hospital CenterDepartment: Medicine/RheumatologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Complement Activation | *Complement System Proteins/im [Immunology] | *Lupus Erythematosus, Systemic/di [Diagnosis] | *Lupus Erythematosus, Systemic/im [Immunology] | Biomarkers/me [Metabolism] | Diagnosis, Differential | Female | Humans | Middle AgedYear: 2016Local holdings: Available online from MWHC library: 1998 - present, Available in print through MWHC library: 1999 - 2006ISSN:
  • 0961-2033
Name of journal: LupusAbstract: Complement activation is a key feature of systemic lupus erythematosus (SLE). Detection of cell-bound complement activation products (CB-CAPS) occurs more frequently than serum hypocomplementemia in definite lupus. We describe a patient with normocomplementemic probable SLE who did not fulfill ACR classification criteria for lupus, but the diagnosis was supported by the presence of CB-CAPS. Copyright � The Author(s) 2016.All authors: Lamichhane D, Weinstein AFiscal year: FY2017Digital Object Identifier: Date added to catalog: 2017-04-11
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 26911153 Available 26911153

Available online from MWHC library: 1998 - present, Available in print through MWHC library: 1999 - 2006

Complement activation is a key feature of systemic lupus erythematosus (SLE). Detection of cell-bound complement activation products (CB-CAPS) occurs more frequently than serum hypocomplementemia in definite lupus. We describe a patient with normocomplementemic probable SLE who did not fulfill ACR classification criteria for lupus, but the diagnosis was supported by the presence of CB-CAPS.

Copyright � The Author(s) 2016.

English

Powered by Koha